

Comparing and combining TSPO-PET tracers in tauopathies

Harry Crook^{1,2*}, Nicolai Franzmeier^{3,4,5*}, Nesrine Rahmouni^{6,7*}, Johannes S Gnörich⁸, Tim Fryer^{1,9}, Young Hong^{1,9}, Sebastian N Roemer-Cassiano^{3,10,11}, Carla Palleis^{4,10,12}, Alexandra Strauss¹, P Simon Jones¹, Franklin I. Aigbirhio¹³, Robert Hopewell⁶, Boris-Stephan Rauchmann^{14,15,16}, Gassan Massarweh¹⁷, Robert Perneczky^{4,12,14,15,18}, Johannes Levin^{10,12}, Günter U Höglinger^{4,10,12}, James B Rowe^{1,19}, John T O'Brien²⁰, Pedro Rosa-Neto^{6,7,21}†, Matthias Brendel^{4,8,12,22}†, and Maura Malpetti^{1,2}†.

* Joint first authors

† Joint senior authorship

Affiliations:

1. Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom
2. UK Dementia Research Institute at University of Cambridge, Cambridge, United Kingdom
3. Institute for Stroke and Dementia Research (ISD), LMU Hospital, LMU Munich, Munich, Germany
4. Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
5. The Sahlgrenska Academy, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, University of Gothenburg, Mölndal and Gothenburg, Sweden
6. McConnell Brain Imaging Centre (BIC), Montreal Neurological Institute, Montreal Neurological Institute-Hospital, Montreal, Quebec, Canada
7. Translational Neuroimaging Laboratory, Research Centre for Studies in Aging, Institution: Douglas Hospital Research Centre - Centre intégré universitaire de santé et services sociaux de l'Ouest-de-l'Île-de-Montréal, Verdun, Quebec, Canada
8. Department of Nuclear Medicine, LMU Hospital, LMU Munich, Munich, Germany
9. Wolfson Brain Imaging Centre, University of Cambridge, Cambridge, United Kingdom
10. Department of Neurology, LMU Hospital, Munich, Germany
11. Max Planck School of Cognition, Leipzig, Germany
12. German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
13. Molecular Imaging Chemistry Laboratory, Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom
14. Institute of Neuroradiology, University Hospital, LMU Munich, Munich, Germany
15. Department of Psychiatry and Psychotherapy, LMU Hospital, LMU Munich, Munich, Germany
16. Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, United Kingdom
17. Department of Radiochemistry, McGill University, Montréal, Quebec, Canada
18. Ageing Epidemiology (AGE) Research Unit, School of Public Health, Imperial College London, London, United Kingdom
19. MRC Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, United Kingdom
20. Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom

21. The Peter O'Donnell Jr. Brain Institute (OBI), University of Texas Southwestern Medical Centre (UTSW).
Dallas, TX, USA

22. Interfaculty Center for Endocrine and Cardiovascular Disease Network Modelling and Clinical
Transfer (ICONLMU), LMU Munich, Munich, Germany

Corresponding author: Dr. Maura Malpetti

University of Cambridge Department of Clinical Neurosciences and
Cambridge University Hospitals NHS Trust, Cambridge, UK.

Email: mm2243@medschl.cam.ac.uk

Acknowledgments

We thank our participant volunteers for their participation in this study, the clinical staff and the research nurses for their contribution, and the East Anglia Dementias and Neurodegenerative Diseases Research Network (DeNDRoN) for help with subject recruitment. We thank all our patients, their caregivers, cyclotron, radiochemistry, and the positron emission tomography imaging staff at LMU Munich. We thank all of our participants and their care partners who contributed to this work at the Montreal Neurological Institute, McGill University.

Abstract

Purpose

Neuroinflammation is a key pathological driver in neurodegenerative diseases, including Alzheimer's disease (AD) and Progressive Supranuclear Palsy (PSP). Positron emission tomography (PET) with tracers targeting the translocator protein (TSPO) enables the in vivo quantification of microgliosis. TSPO tracers have shown similar disease-specific patterns across cohorts. However, direct quantitative comparisons between commonly used TSPO-PET tracers in tauopathies have not been performed. Here, we apply a TSPO-PET standardization pipeline across clinically matched AD cohorts and PSP cohorts, to quantify, compare and combine multi-centre TSPO-PET data.

Methods

Patients with PSP were scanned with either [¹¹C]PK11195 or [¹⁸F]GE-180 at one of two centres, while patients with AD and control participants were scanned with either [¹¹C]PK11195, [¹⁸F]GE-180 or [¹¹C]PBR28 at one of three centres. A standardised pre-processing pipeline was implemented and participant standardised uptake volume ratio (SUVR) values were z-scored using tracer-specific control participant values. In a data-driven approach, dissimilarity analyses were employed to assess differences between tracers across clinically matched cohorts.

Results

In PSP, dissimilarity analysis suggested that [¹¹C]PK11195 and [¹⁸F]GE-180 binding patterns were comparable following standardisation. In AD, comparability across tracers was less robust, with [¹¹C]PK11195 and [¹⁸F]GE-180 being most comparable, followed by [¹⁸F]GE-180 vs [¹¹C]PBR28, then by [¹¹C]PK11195 vs [¹¹C]PBR28.

Conclusion

The pipeline was effective at harmonising TSPO-PET tracers and standardising the regional quantification of neuroinflammation in clinically matched cohorts of PSP, while the standardisation pipeline results were less robust across AD cohorts.

Keywords

Neuroinflammation, Positron Emission Tomography, Translocator Protein, Progressive Supranuclear Palsy, Alzheimer's Disease.

Introduction

The 18kDa translocator protein (TSPO) is expressed on the outer mitochondrial membrane within cells of organs including the kidneys, lungs, heart, and brain [1]. While the exact role of TSPO in the central nervous system remains elusive, its upregulation is linked to the proliferation, migration, and phagocytic functions of microglia, as well as the maintenance of mitochondrial homeostasis and the release of inflammatory cytokines [2]. In neurodegenerative disease, TSPO has been shown to be upregulated in microglia [3-5], and to a lesser extent in astrocytes and vasculature. For these reasons, TSPO has been considered a marker of neuroinflammation. Hence, positron emission tomography (PET) radiotracers have been developed that specifically target TSPO to measure *in vivo* tissue neuroinflammatory response in patients with dementia and other conditions.

Neuroinflammation is a key pathological feature of all neurodegenerative diseases [6], and TSPO-PET has been shown to be a useful marker to quantify neuroinflammation *in vivo* across neurodegenerative diseases. Indeed, heightened levels of neuroinflammation, as measured by TSPO-PET binding, has been associated with a greater rate of cognitive decline and disease progression in progressive supranuclear palsy (PSP) [7], frontotemporal dementia [8], Alzheimer's disease (AD) dementia, and mild cognitive impairment (MCI) [9, 10], while high TSPO-PET binding in early stages increases the risk of developing dementia in patients with Parkinson's disease [11]. Moreover, neuroinflammation has been associated with brain network dysfunction, as measured with resting state functional magnetic resonance imaging (MRI) [12], and the neuroinflammatory signal strongly correlates with neuropathological substrates topographically, especially tau protein, in both primary and secondary tauopathies [13-18]. Across diseases, patients with high TSPO-PET binding also exhibit elevated levels of inflammatory proteins in cerebrospinal fluid [19] and serum [20].

Several TSPO tracers have been developed, including the carbon-11 radiolabelled first-generation tracers such as PK11195 (1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinoline carboxamide) and Ro5-4864 (4'-chlorodiazepam). While [¹¹C]Ro5-4864 binding varies due to temperature and species, [¹¹C]PK11195 has a high affinity and selectivity to TSPO and has been widely used to study neuroinflammation [21]. Despite the success of [¹¹C]PK11195, its drawbacks, including a short half-life, low signal-to-noise ratio, and variable kinetics, have encouraged the development of second- and third-generation tracers. These tracers include [¹¹C]PBR28, [¹¹C]ER176, as well as the fluorine-18 radiolabelled tracers [¹⁸F]DPA-714, and [¹⁸F]GE-180, which have extended half-lives compared to carbon-11 labelled tracers. Although the second- and third-generation tracers display greater signal-to-noise than their predecessors, a common single nucleotide polymorphism (rs6971) in the TSPO gene affects their binding affinity, meaning that participants can have a high-, mixed-, or low- affinity binding and those in the latter group cannot be effectively imaged with these more recently developed tracers [22-25]. Despite its lower signal-to-noise ratio, [¹¹C]PK11195 is minimally affected by this genetic variable.

Despite differences across tracers, previous studies in clinically matched cohorts of patients with tauopathies have identified regional patterns of increased TSPO-PET signal, which parallel known regional patterns of tau aggregates. For example, when compared to healthy volunteers, temporal, parietal, and occipital regions demonstrate elevated TSPO-PET binding in AD [26-28], while in the primary tauopathy PSP, the thalamus, putamen, pallidum, and midbrain are the most affected regions [15, 26, 29].

Although head-to-head studies comparing different TSPO-PET tracers have been conducted in small groups of healthy controls [30, 31], direct and quantitative comparisons from distinct patient cohorts with tauopathies imaged using various TSPO-PET tracers have not been reported. The goal of this study, therefore, is to enhance the utility of TSPO-PET imaging in tauopathies by harmonising the processing pipelines in order to compare and combine tracers. Should this methodology prove effective, it will allow for the creation of multicentre databases larger than those achievable with institution-specific cohorts, as well as a harmonised pipeline and universal scales to estimate microglial activation severity irrespective of the TSPO-PET tracer in use. Here, we describe the harmonised processing pipeline and the dissimilarity analyses that we have undertaken to assess the strength and validity of this pipeline. We have included patients with primary tauopathy PSP and secondary tauopathy AD to test this process across three centres and TSPO-PET tracers.

Material and methods

Participant cohorts

Patients with a clinical diagnosis of PSP Richardson's syndrome (PSP-RS) [32], or of MCI due to AD (MCI-AD) and/or Alzheimer's Dementia [33, 34], alongside age- and sex-matched cognitively unimpaired controls, were recruited across three centres: the University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; LMU Hospital, Ludwig-Maximilians Universität München, Munich, Germany; and McGill University and Montreal Neurological Institute Hospital, Montreal, Canada. All participants provided written informed consent according to the Declaration of Helsinki.

Specifically, 18 patients with PSP-RS, 32 patients with AD (14 AD and 18 MCI-AD), and 15 control participants underwent [¹¹C]PK11195 PET in Cambridge; 17 patients with PSP-RS, 40 patients with AD, and 19 control participants underwent [¹⁸F]GE-180 PET in Munich; 25 patients with AD (11 AD and 14 MCI-AD) and 25 control participants underwent [¹¹C]PBR28 PET in Montreal.

All participants undertook a detailed clinical and cognitive assessment. All patients with PSP-RS completed the PSP rating scale [35], while patients with AD completed either the Mini-mental state examination (MMSE) [36] or the Montreal cognitive assessment (MoCA) [37].

PET acquisition

[¹¹C]PK11195 PET was undertaken at the Wolfson Brain Imaging Centre at the University of Cambridge, United Kingdom. Scans were performed on GE Advance and GE Discovery 690 PET/CT (GE Healthcare) scanners with a 15-min 68Ge/68Ga transmission computed tomography (CT) scan for attenuation correction. 500 MBq of [¹¹C]PK11195 with a specific activity of around 85 GBq/μmol was injected intravenously over 30-seconds at the onset of a 75-minute dynamic scan.

[¹⁸F]GE-180 PET was undertaken at Ludwig Maximilian University of Munich, Germany. These scans were completed on a Siemens Biograph True point 64 PET/CT or a Siemens mCT PET/CT scanner (Siemens, Erlangen, Germany) with CT used in combination for attenuation correction. 185 MBq of [¹⁸F]GE-180 with a specific activity of >1500 GBq/μmol was injected intravenously and PET images acquired statically at 60-80 minutes post-injection.

[¹¹C]PBR28 PET was undertaken at the Brain Imaging Centre, Montreal Neurological Institute, McGill University, Canada. Scans were performed on a Siemens high-resolution research tomograph with a 6-min transmission scan performed at the end of each PET emission acquisition for attenuation correction. A mean dose of 384 MBq of [¹¹C]PBR28 with a specific activity of around 193 GBq/μmol was injected intravenously, and emission PET images were acquired from 0-90 minutes and reconstructed from 60-90 minutes.

All TSPO-PET data was visually checked for scan quality and artifacts prior to preprocessing.

To ensure accuracy and comparability of TSPO binding measurements, all participants that were low affinity binders due to the TSPO polymorphism rs6971 and underwent [¹⁸F]GE-180 PET or [¹¹C]PBR28 PET were removed from the analysis following genetic testing after PET imaging [24].

Harmonised PET pre-processing pipeline

A 40-70 minute time window after injection from the dynamic [¹¹C]PK11195 PET scans was considered to calculate the standardised uptake value ratio (SUVR), which was selected based on the correlation between SUVR and distribution volume ratio for various SUVR time windows, as well as the stability of the SUVR values. The [¹⁸F]GE-180 signal, meanwhile, was recorded 60-80 minutes after injection and [¹¹C]PBR28 was recorded at 60-90 minutes post-injection to calculate SUVR.

Each [¹¹C]PK11195 PET image was co-registered to the corresponding T1-weighted MR image and kept in subject space, while each [¹⁸F]GE-180 and [¹¹C]PBR28 PET images were transformed to Montreal Neurological Institute (MNI) space. Inverse transform parameters were applied to a modified version of the Hammers Atlas [38] to bring the regions of interest (ROI) to scan-specific space. The modified version of the atlas allowed for the inclusion of brainstem regions into the analysis which are important regions to include for the assessment of patients with PSP-RS.

All PET images were intensity normalised to mean tracer uptake of a shared reference region of the cerebellar grey matter in order to determine the SUVR. The reference region was defined from the Hammers cerebellum ROI with manual adjustment, excluding the dentate nucleus, and superior and posterior layers. While the dentate nucleus and cerebellar white matter is affected by pathology in PSP-RS, the cerebellar grey matter is often spared until later disease stages [39]. Grey matter in the cerebellum is also spared of pathology, including inflammation, until late-stage AD [40, 41]. All participants included in this study were in the mild to moderate stages of their disease, therefore we used cerebellar grey matter as optimal reference region across the three tracers and the two diseases (PSP and AD) included in the study. A similar reference region has been used in previous dementia studies with TSPO PET tracers [42]. In order to maintain harmony between the processing of the tracers, vascular binding correction and partial volume correction was not applied. Averaged SUVR values across grey and white matter from the Hammers atlas ROIs were extracted from each participant.

Z-scoring

Corresponding left and right regional SUVR values from the Hammers atlas were averaged to obtain bilateralised regional SUVR values. To standardise the SUVR scales, z-scores for each

region were calculated for each patient, based on centre-specific control participants. The following formula was employed to calculate Z-scores:

$$[^{11}\text{C}]PK11195 \text{ Participant Z Score} = \frac{SUVR_{region} - \text{Region Control Mean}_{[^{11}\text{C}]PK11195}}{\text{Region Control SD}_{[^{11}\text{C}]PK11195}}$$

$$[^{18}\text{F}]GE - 180 \text{ Participant Z Score} = \frac{SUVR_{region} - \text{Region Control Mean}_{[^{18}\text{F}]GE-180}}{\text{Region Control SD}_{[^{18}\text{F}]GE-180}}$$

$$[^{11}\text{C}]PBR28 \text{ Participant Z Score} = \frac{SUVR_{region} - \text{Region Control Mean}_{[^{11}\text{C}]PBR28}}{\text{Region Control SD}_{[^{11}\text{C}]PBR28}}$$

Statistical analysis

Due to some regional z-scored SUVR values having a non-normal distribution and not meeting assumptions for parametric tests, non-parametric statistical tests were employed. We applied the same combination of dissimilarity analyses separately for PSP-RS and AD cohorts, to determine whether any tracer-specific differences could be identified within disease groups.

First, to compare $[^{11}\text{C}]PK11195$ and $[^{18}\text{F}]GE-180$ regional z-scores in the PSP-RS and control groups two-sided, Mann-Whitney U tests were employed, while Kruskal-Wallis and post-hoc Dunn's tests were used to compare regional z-scores of all three tracers in the AD and control groups. These analyses were adjusted for multiple comparisons using false discovery rate (FDR) correction.

Second, a full factorial analysis was implemented to systematically examine the effects of the diagnostic group, TSPO-PET tracer, and brain region, on the regional z-score. A main effects model (z-score ~ diagnostic group + tracer + region + age + sex), as well as a model to examine two-factor interactions (z-score ~ diagnostic group:tracer + region + age + sex) and three-factor interactions (z-score ~ diagnostic group:tracer:region + age + sex) was applied. For the two- and three-factor interaction models, family-wise error corrected post-hoc estimated marginal means analyses were employed to identify interaction effects. Due to having z-scores closest to 0 for both PSP-RS and AD groups, the precentral gyrus was used as the reference region for this model to compare to all other brain regions.

Then, Euclidean distance was used to calculate the distance between each participants z-scores in forty-one-dimensional space, based on 41 brain regions of interest, and clustering algorithms were run to visualise the distance and any clustering of participants based on tracer. Hierarchical agglomerative clustering was used as a data exploration tool to assess how closely participants cluster, with a dendrogram fitted to visualise any clustering based on PET tracer. K-means clustering of Euclidean distances was also applied with two clusters set for the PSP-RS group and three for the AD group.

Finally, to observe the pairwise dissimilarities of regional z-scores between tracers, representational similarity analysis was implemented using correlation distance (1 minus the correlation coefficient) for each brain region. To further explore the patterns in the dissimilarity matrices computed by the representational similarity analysis, pattern similarity using Spearman's correlation between tracer matrices was performed to evaluate the correlation

between dissimilarities observed in the matrices. Lastly, permutation testing with 5000 simulations was implemented to assess the likelihood that any of the observed correlations between the tracers could have occurred by chance.

All statistical analyses were conducted in R version 4.3.2 (2023-10-31) [43]. A significance level of $p < 0.05$ was applied throughout.

Results

Participants and demographics

Participant numbers and demographics are listed in table 1. For 8 out of 40 patients with AD who underwent [^{18}F]GE-180 PET, MMSE scores were obtained with score conversion from MoCA using a pre-established approach [44].

Harmonisation across PSP-RS cohorts: [^{11}C]PK11195 and [^{18}F]GE-180 results

Several dissimilarity analyses were run to determine whether any tracer-specific differences could be identified.

Pairwise comparisons

No differences in z-scores were observed between tracers for any brain region in control participants. In PSP-RS, there were no differences in z-scores between tracers for any region except the subcallosal area ($p = 0.04$) (Figure 1).

Full factorial analysis

The main effects model ($z\text{-score} \sim \text{diagnostic group} + \text{tracer} + \text{region} + \text{age} + \text{sex}$) was significant ($F(44, 2784) = 3.881, p < 0.001$). There was a significant main effect of tracer on predicting z-score ([^{11}C]PK11195 - [^{18}F]GE-180, $\text{est.} = 0.089, p = 0.041$), suggesting a difference between the two tracers. Main effects of diagnostic group ($\text{est.} = 0.136, p = 0.002$), age ($\text{est.} = 0.033, p < 0.001$), and sex ($\text{est.} = -0.245, p < 0.001$) to predict z-score were also observed. Of the 40 brain regions considered, the anterior superior temporal gyrus ($\text{est.} = -0.435, p = 0.027$) and the pallidum ($\text{est.} = 0.428, p = 0.014$) showed a significant predictive effect of z-score in relation to the precentral gyrus.

To explore the interaction between main effects, a two-factor interaction model ($z\text{-score} \sim \text{diagnostic group}:\text{tracer} + \text{region} + \text{age} + \text{sex}$) was performed. The model was significant ($F(45, 2783) = 3.85, p < 0.001$), however, no interaction effect between diagnostic group and tracer was found ($\text{est.} = 0.130, p = 0.136$).

A three-factor interaction model ($z\text{-score} \sim \text{diagnostic group}:\text{tracer}:\text{region} + \text{age} + \text{sex}$) was run to assess the interaction between diagnostic group and tracer for each region to predict z-score. This model was significant ($F(165, 2663) = 1.82, p < 0.001$), with the subcallosal area showing a significant interaction effect with diagnostic group and tracer ($\text{est.} = -0.312, p = 0.034$).

Full output of the full factorial analyses can be found in supplementary table 1.

Euclidean distance with hierarchical clustering

A Euclidean distance matrix was generated to visualise the pairwise dissimilarity between participants, based on z-scores of all brain regions. Figure 2 details the Euclidean distance matrices where hierarchical clustering of patients with PSP-RS (Figure 2a) and controls participants (Figure 2b) was employed. Supplementary figure 1 depicts Euclidean distance matrices where participants were clustered with K-means clustering.

Representational similarity analysis with pattern similarity and permutation testing

Representational similarity analysis identified similar z-score patterns in patients with PSP-RS regardless of tracer (Figure 3). This was confirmed with pattern similarity between matrices ($r=0.42$) and permutation testing which demonstrated that it is highly unlikely this was a chance finding (Supplementary Figure 2). Although the relationship between z-score patterns in control participants was also significant ($r=0.24$) permutation testing highlighted that this finding could be due to chance (Supplementary Figure 1).

Harmonisation across AD cohorts: [¹¹C]PK11195, [¹⁸F]GE-180 and [¹¹C]PBR28 results

Several dissimilarity analyses were run to determine whether any tracer-specific differences could be identified across the AD-specific cohorts.

Pairwise comparisons

No differences in z-scores were observed between tracers for any brain region in control participants. In patients with AD, [¹¹C]PK11195 had significantly greater binding than [¹⁸F]GE-180 in the pons ($p=0.010$) and pallidum ($p=0.02$), and significantly greater binding than [¹¹C]PBR28 in the amygdala ($p=0.002$), medial anterior temporal lobe ($p=0.04$), and thalamus ($p=0.03$). [¹⁸F]GE-180 showed higher binding than [¹¹C]PBR28 in the hippocampus ($p=0.04$) and amygdala ($p=0.004$), and higher binding than [¹¹C]PK11195 in the subcallosal area ($p=0.03$). In the anterior cingulate, [¹¹C]PBR28 demonstrated greater binding than [¹⁸F]GE-180 ($p=0.03$) (Figure 4).

Full factorial analysis

The main effects model ($z\text{-score} \sim \text{diagnostic group} + \text{tracer} + \text{region} + \text{age} + \text{sex}$) was significant ($F(45, 6350)=1.847, p<0.001$), with a significant main effect seen when comparing [¹¹C]PK11195 and [¹¹C]PBR28 (est.=0.135, $p=0.003$) but not when comparing [¹¹C]PK11195 and [¹⁸F]GE-180 or [¹⁸F]GE-180 and [¹¹C]PBR28. While no main effect of age or sex was found, the amygdala (est.=0.301, $p=0.037$), caudate nucleus (est.=-0.381, $p=0.008$), and superior temporal gyrus anterior part (est.=-0.316, $p=0.028$) showed significant effects on the model.

To explore the interaction between main effects, a two-factor interaction model ($z\text{-score} \sim \text{diagnostic group:tracer} + \text{region} + \text{age} + \text{sex}$) was performed and was significant ($F(47,$

6348)=1.91, $p < 0.001$). Post-hoc analysis revealed that the difference between [^{11}C]PK11195 and [^{11}C]PBR28 in patients with AD (est.=0.222, $p < 0.001$) was the main driver of the significance of this model.

A three-factor interaction model (z-score ~ diagnostic group:tracer:region + age + sex) was run to assess the interaction between diagnostic group and tracer for each region to predict z-score. Overall, this model was not significant ($F(247, 6148)=1.11$, $p=0.12$), with the only significant interaction effect again being between [^{11}C]PK11195 and [^{11}C]PBR28 in the amygdala (est=1.50, $p=0.048$).

Full output of the full factorial analysis can be found in supplementary table 2.

Euclidean distance with hierarchical clustering

A Euclidean distance matrix was generated to demonstrate the pairwise dissimilarity between AD and control participants, based on z-scores of all brain regions. Figure 5 details the Euclidean distance matrices where hierarchical clustering of patients with AD (Figure 5a) and control participants (Figure 5b) was employed. Supplementary figure 3 depicts Euclidean distance matrices with participants clustered using K-means clustering.

Representational similarity analysis with pattern similarity and permutation testing

In the AD group, representational similarity analysis and pattern similarity of matrices identified similar z-score patterns between [^{11}C]PK11195 and [^{18}F]GE-180 ($r=0.36$), and between [^{18}F]GE-180 and [^{11}C]PBR28 ($r=0.26$) (Figure 6). Permutation testing of the weak correlation of patterns seen between [^{11}C]PK11195 and [^{11}C]PBR28 ($r=0.15$) (Figure 6) found that this was likely a chance finding (Supplementary Figure 4). Robust, however weak, correlations between tracers were seen in the control group; [^{11}C]PK11195 and [^{18}F]GE-180 ($r=0.24$), [^{18}F]GE-180 and [^{11}C]PBR28 ($r=0.33$), [^{11}C]PK11195 and [^{11}C]PBR28 ($r=0.24$) (Figure 6).

Discussion

With the aim of harmonising and comparing TSPO-PET tracers across clinically matched cohorts of patients with primary and secondary tauopathies, we developed and applied a standardised pre-processing pipeline across three cohorts. We included patients with PSP-RS scanned with either [^{11}C]PK11195 or [^{18}F]GE-180, patients with AD scanned with either [^{11}C]PK11195, [^{18}F]GE-180, or [^{11}C]PBR28, as well as control participants scanned with either of the three tracers. Overall, our multivariate approach and dissimilarity analyses converged to suggest that our new pipeline to harmonise TSPO-PET tracers and standardise the regional quantification of neuroinflammation is effective for [^{11}C]PK11195 and [^{18}F]GE-180 in PSP-RS. Due to its homogeneous and symmetrical neuropathological profile, PSP-RS is an excellent model disease to develop harmonisation and standardisation methodologies for TSPO-PET quantification across tracers. When applied to cohorts of patients with AD across three distinct tracers, the standardisation pipeline was less robust, with dissimilarity analyses highlighting that [^{18}F]GE-180 and [^{11}C]PK11195 were the most comparable, followed by [^{18}F]GE-180 and [^{11}C]PBR28, and lastly by [^{11}C]PK11195 and [^{11}C]PBR28.

With the emergence of novel, clinically meaningful, disease-modifying therapies for neurodegenerative diseases [45], efforts have been directed to harmonise methods that quantify the magnitude of neuropathological changes. For example, the Centiloid project [46] has revolutionised how amyloid- β pathology is evaluated based on a scale applicable to different amyloid-PET tracers, which allows for comparable amyloid measurements across tracers, cohorts and centres. This method has been particularly useful in trials of anti-amyloid therapies [47, 48]. Other efforts, such as the CenTauR [49] or Uni-Tau from HEAD studies [50] aim to standardise the quantification of tau pathology across tau-PET tracers and centres. While the interpretation of the TSPO-PET signal in humans remains a controversial topic, a recent study validated the signal using post-mortem tissue from patients with PSP who underwent TSPO-PET during life. Microglial levels of TSPO positively correlated with the ante-mortem TSPO-PET signal [4], reinforcing that this imaging tool provides a useful window to shed light on the levels of neuroinflammation that may be occurring within the brain. Despite notable limitations - including its short half-life, lower molar activity relative to [^{18}F]-labelled tracers, high non-specific binding, and a relatively low signal-to-noise ratio - [^{11}C]PK11195 has been extensively used as a TSPO-PET imaging probe for several decades. Crucially, its insensitivity to the rs6971 polymorphism in the TSPO gene enables more straightforward comparison across past and future datasets. Among the second-generation tracers, [^{11}C]PBR28 provides a markedly improved signal-to-noise ratio and has been widely applied in studies of neurodegenerative disease. However, its binding affinity is influenced by the TSPO polymorphism, with the highest incidence of low-affinity binders reported in Caucasian populations [51], making subject genotyping necessary. More recently, third-generation tracers such as [^{18}F]GE-180 have reduced dependence on genotype, as they show comparable binding in high- and mixed-affinity binders, though binding remains low in low-affinity binders [52]. Additionally, the longer half-life of [^{18}F]-labelled tracers extends clinical applicability, including at sites without on-site cyclotron or radiochemistry facilities. Nonetheless, [^{18}F]GE-180 is limited by its relatively low blood-brain barrier penetration. With increasing evidence on the key role of microglia-mediated inflammation in neurodegenerative diseases [53], and inflammation-targeting drugs under evaluation in several clinical trials [54], as well as the practical challenges of adopting a gold standard TSPO-PET tracer globally, methods that enable harmonisation and combination of TSPO-PET tracers across centres are urgently needed to improve target-engagement evaluation, patient stratification and monitoring.

Using z-scores against centre- and tracer-specific controls, comparisons across brain regions demonstrated that tracers were comparable for 100% (41/41) of regions in control participants, 98% (40/41) of regions in patients with PSP-RS (Figure 1), and 80% (33/41) of regions in patients with AD (Figure 4). As z-scoring forced the mean of the control groups to zero, it was expected that no difference would be seen between tracers in this group. In patients with PSP-RS, tau deposition is usually predominant in subcortical regions with symmetrical patterns, before spreading throughout the cortex in later stages of the disease [39, 55]. Neuroinflammation has been shown to colocalise with and parallel the progression of tau pathology [15]. The high homogeneity of pathology seen in PSP-RS may be reflected in the similarities seen between tracers here, and highlight that the two tracers examined here can be compared in this disease group following harmonisation. In AD, although tau pathology usually follows Braak stages [56], the widespread presence of amyloid makes the neuroinflammatory profile much more heterogeneous in these patients compared to in PSP-RS [13, 26]. The heterogeneous nature of neuroinflammation in AD may be the reason why fewer regions were comparable between the three tracers, as patients with AD have more variable brain inflammation profiles. Furthermore, the AD cohort consisted of patients with either AD or MCI-AD, which may have resulted in the

variability observed due to the greater range of disease severity in comparison to the PSP-RS group, which all had established disease and diagnoses.

We ran full factorial analyses to evaluate the main, two-, and three-factor interaction effects of tracer, diagnosis, brain region, age, and sex to predict TSPO-PET z-scores. This analysis demonstrated the presence of a main effect of tracers on the model in the PSP-RS cohort suggesting a difference between [¹¹C]PK11195 and [¹⁸F]GE-180 in this group, however this effect was marginal (p=0.041) and may have been explained by other variables, such as diagnostic group, age, and sex. As expected, the diagnostic group variable, defined as PSP-RS vs control cohorts, showed a main effect on z-score prediction, as patients with PSP-RS generally have greater levels of neuroinflammation. Also reassuringly due to its impact in PSP-RS, the pallidum showed a significant predictive effect of z-score in the model. Significant interaction effects were identified when age and/or sex, and PSP-RS-affected regions, such as the subcallosal area, were included in interaction terms with the tracer variable. In the AD group, post-hoc analysis of the main effects model suggested that a significant effect was found when comparing between [¹¹C]PK11195 and [¹¹C]PBR28, further highlighting that either tracer or patient-specific differences may be present in this group. Several interaction effects involving the tracer were also found. Sex and age consistently demonstrated significant main and interaction effects in these models, both in PSP-RS and AD. Sex differences in TSPO-PET binding have been identified in AD, with females showing greater binding than males [57]. App^{NL-G-F} Amyloidosis mouse models of AD replicate this finding but this is not seen in P301S mice exhibiting tau pathology [58]. It is now also largely proven that inflammation increases with age, with inflammaging being a risk factor for developing neurodegenerative disease [59]. However, further studies are needed to fully understand age- and sex-specific differences related to the TSPO signal and microglia-mediated cascades in tauopathies.

To further test our standardisation pipeline, Euclidean distances were calculated for each participant, based on all forty-one brain regions and clustered using two separate methods to visualise any tracer-specific clustering. Firstly, for patients with PSP-RS and controls, the hierarchical clustering algorithm demonstrated that individual inflammation patterns (i.e. single participants) were evenly distributed across the dendrogram, regardless of whether their TSPO levels were quantified with [¹¹C]PK11195 or [¹⁸F]GE-180 (Figure 2). Next, K-means clustering with two clusters was used, and each data-driven cluster included participants from both tracer cohorts in both PSP-RS and control groups (Supplementary Figure 1), suggesting that the standardisation pipeline was effective. In patients with AD and controls scanned with [¹¹C]PK11195, [¹⁸F]GE-180, or [¹¹C]PBR28, again the control participants were evenly spread across the dendrogram when hierarchical clustering was used, and all three of the K-means clusters contained a mixture of all three tracers (Supplementary Figure 3). In the AD cohort, however, one small cluster containing five patients scanned with [¹¹C]PBR28 and one with [¹¹C]PK11195 clustered separately from all other participants, who were instead evenly spread across the rest of the matrix (Figure 5). These 6 patients had consistently low TSPO-PET z-scores compared to other participants throughout the brain; four of them were male and relatively unimpaired cognitively, with MMSE scores ≥ 24 . As studies have demonstrated discrepancies in TSPO-PET binding as a result of factors such as sex (as well as age and body mass index) in both mice and humans [58, 60, 61], further work is needed to understand individual differences in TSPO-PET binding in both healthy and diseased brains.

Lastly, a representational similarity analysis was run to visualise any regional z-score patterns between tracers. This was followed by a pattern similarity analysis of the representational

similarity matrices to quantify the correlation between the tracers. As with previous analyses in the PSP-RS cohorts, [¹¹C]PK11195 and [¹⁸F]GE-180 showed comparable z-score patterns across the brain, a result that permutation testing confirmed was robust (Supplementary Figure 2), which coincides with tau deposition [15], and further supports the comparability of these two tracers following implementation of the standardisation pipeline. In AD, a similarly strong and robust z-score pattern was seen for both [¹¹C]PK11195 and [¹⁸F]GE-180, while [¹⁸F]GE-180 and [¹¹C]PBR28 patterns were also statistically similar (Figure 6). Corroborating the results of the full factorial analysis, [¹¹C]PK11195 and [¹¹C]PBR28 regional z-scores patterns were not statistically similar in this AD cohort following standardisation, emphasising either tracer or cohort differences between these two groups. For control participants, weak but robust correlations in z-score patterns were seen between the three tracers, possibly highlighting a generalised pattern of background neuroinflammation ongoing in the brain to alleviate everyday insults, as well as confirming the absence of any specific neuropathology in these participants.

The differences observed between tracers here could be due to several factors: first, the differences may be tracer-specific, and our standardisation pipeline may need to be optimised for each tracer, as suggest by Maccioni and colleagues for their models [62]. For example, tracer-specific optimisation may need to account for the proportion of mixed and high affinity binders as well as the brain regions considered in the analyses, for which the signal may vary based on the tracer and the disease cohort of interest. Furthermore, analyses may require an optimised SUVR time window and reference region that are tracer-specific to account for differences in their delivery and kinetics. The optimisation for one tracer may not directly translate to others, and it is important to test these variations. Second, differences may also occur as a result of hardware discrepancies. As well as using different tracers, different PET scanners were used in Cambridge, Munich, and Montreal, which is an unavoidable difference that must be considered and appreciated in multi-centre imaging studies. Moving forward, a collaborative effort must address how best to account for differences in scanner outputs. Third, although clinically matched, the AD cohorts consisted of both patients with AD and patients with MCI-AD which may have increased the variation in neuroinflammation in these groups and affected their comparability. Lastly, neuroinflammation is a dynamic process, both in healthy and diseased brain states [6, 63, 64], therefore it is more difficult than for other pathological hallmark to fully match cohorts of people without scanning the same individuals with different tracers within a short timeframe. Indeed, head-to-head studies of TSPO-PET radiotracers have been completed, however these are limited to healthy volunteers only [30, 31]. It is therefore also likely that, especially in a heterogeneous disease like AD, individual patient differences could affect the performance of the standardisation pipeline. In addition to the increased variability possibly added by including patients with MCI-AD in the AD cohort, differences in PET scanners used at each centre may have introduced variation in the PET outputs and may have an inflated variability seen between tracers.

Together, our work suggests that harmonisation pipelines for TSPO-PET tracers can be applied for PSP-RS, likely due to the homogeneous and symmetrical neuropathological profile of PSP-RS rendering it an excellent model disease to develop harmonisation and standardisation methodologies for TSPO-PET quantification across tracers. We found, however, that when applied to patients with AD across three distinct tracers, our standardisation pipeline was less robust, with dissimilarity analyses highlighting that [¹⁸F]GE-180 and [¹¹C]PK11195 were the most comparable, followed by [¹⁸F]GE-180 and [¹¹C]PBR28, and lastly by [¹¹C]PK11195 and [¹¹C]PBR28. Ongoing work aims to further optimise and scrutinise standardisation pipelines, whilst expanding the approach to larger cohorts, a greater number of tracers, and other neurodegenerative diseases. It will be important to validate and expand this work to develop thresholds of

“neuroinflammation severity” using multiple TSPO-PET tracers related to clinical and cognitive outcomes in order to allow for the creation of multi-centre databases, larger than those which could be created at a single site. The final goal is to have powerful TSPO-PET studies, where large cohorts can be analysed and compared quantitatively to inform clinical trials targeting inflammation and provide an objective and reliable outcome and/or monitoring measure.

Ethics approval

This study was performed in line with the principles of the Declaration of Helsinki. The following ethics approvals were granted: The research protocol for Cambridge data were approved by the National Research Ethics Service’s East of England Cambridge Central Committee, and the UK Administration of Radioactive Substances Advisory Committee. The study protocol for LMU Munich data was approved by the Ethics Committee of LMU Munich and the Bundesamt für Strahlenschutz (project numbers 17-755 and 17-569).

The protocol for the TRIAD study was approved by the Montreal Neurological Institute PET working committee and the Douglas Mental Health University Institute Research Ethics Board.

References

1. Nutma E, Ceyzeriat K, Amor S, Tsartsalis S, Millet P, Owen DR, et al. Cellular sources of TSPO expression in healthy and diseased brain. *Eur J Nucl Med Mol Imaging*. 2021;49:146-63. doi:10.1007/s00259-020-05166-2.
2. Cheung G, Lin YC, Papadopoulos V. Translocator protein in the rise and fall of central nervous system neurons. *Front Cell Neurosci*. 2023;17:1210205. doi:10.3389/fncel.2023.1210205.
3. Garland EF, Antony H, Kulagowska L, Scott T, Rogien C, Bottlaender M, et al. The microglial translocator protein (TSPO) in Alzheimer's disease reflects a phagocytic phenotype. *Acta Neuropathol*. 2024;148:62. doi:10.1007/s00401-024-02822-x.
4. Wijesinghe SS, Rowe JB, Mason HD, Allinson KSJ, Thomas R, Vontobel DS, et al. Post-mortem validation of in vivo TSPO PET as a microglial biomarker. *Brain*. 2025. doi:10.1093/brain/awaf078.
5. Gui Y, Marks JD, Das S, Hyman BT, Serrano-Pozo A. Characterization of the 18 kDa translocator protein (TSPO) expression in post-mortem normal and Alzheimer's disease brains. *Brain Pathol*. 2020;30:151-64. doi:10.1111/bpa.12763.
6. Guzman-Martinez L, Maccioni RB, Andrade V, Navarrete LP, Pastor MG, Ramos-Escobar N. Neuroinflammation as a Common Feature of Neurodegenerative Disorders. *Front Pharmacol*. 2019;10:1008. doi:10.3389/fphar.2019.01008.
7. Malpetti M, Passamonti L, Jones PS, Street D, Rittman T, Fryer TD, et al. Neuroinflammation predicts disease progression in progressive supranuclear palsy. *J Neurol Neurosurg Psychiatry*. 2021;92:769-75. doi:10.1136/jnnp-2020-325549.
8. Malpetti M, Cope TE, Street D, Jones PS, Hezemans FH, Mak E, et al. Microglial activation in the frontal cortex predicts cognitive decline in frontotemporal dementia. *Brain*. 2023;146:3221-31. doi:10.1093/brain/awad078.
9. Malpetti M, Kievit RA, Passamonti L, Jones PS, Tsvetanov KA, Rittman T, et al. Microglial activation and tau burden predict cognitive decline in Alzheimer's disease. *Brain*. 2020;143:1588-602. doi:10.1093/brain/awaa088.
10. Leng F, Hinz R, Gentleman S, Dani M, Brooks DJ, Edison P. Combined Neuroinflammation and Amyloid PET Markers in Predicting Disease Progression in Cognitively Impaired Subjects. *J Alzheimers Dis*. 2024;100:973-86. doi:10.3233/JAD-230442.

11. Kouli A, Spindler LRB, Fryer TD, Hong YT, Malpetti M, Aigbirhio FI, et al. Neuroinflammation is linked to dementia risk in Parkinson's disease. *Brain*. 2024;147:923-35. doi:10.1093/brain/awad322.
12. Leng F, Hinz R, Gentleman S, Hampshire A, Dani M, Brooks DJ, et al. Neuroinflammation is independently associated with brain network dysfunction in Alzheimer's disease. *Mol Psychiatry*. 2023;28:1303-11. doi:10.1038/s41380-022-01878-z.
13. Pascoal TA, Benedet AL, Ashton NJ, Kang MS, Therriault J, Chamoun M, et al. Microglial activation and tau propagate jointly across Braak stages. *Nat Med*. 2021;27:1592-9. doi:10.1038/s41591-021-01456-w.
14. Malpetti M, Roemer SN, Harris S, Gross M, Gnorich J, Stephens A, et al. Neuroinflammation Parallels 18F-Pi-2620 Positron Emission Tomography Patterns in Primary 4-Repeat Tauopathies. *Mov Disord*. 2024;39:1480-92. doi:10.1002/mds.29924.
15. Malpetti M, Passamonti L, Rittman T, Jones PS, Vazquez Rodriguez P, Bevan-Jones WR, et al. Neuroinflammation and Tau Colocalize in vivo in Progressive Supranuclear Palsy. *Ann Neurol*. 2020;88:1194-204. doi:10.1002/ana.25911.
16. Dani M, Wood M, Mizoguchi R, Fan Z, Walker Z, Morgan R, et al. Microglial activation correlates in vivo with both tau and amyloid in Alzheimer's disease. *Brain*. 2018;141:2740-54. doi:10.1093/brain/awy188.
17. Parbo P, Ismail R, Hansen KV, Amidi A, Marup FH, Gottrup H, et al. Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer's disease. *Brain*. 2017;140:2002-11. doi:10.1093/brain/awx120.
18. Finze A, Biechele G, Rauchmann BS, Franzmeier N, Palleis C, Katzdobler S, et al. Individual regional associations between A β -, tau- and neurodegeneration (ATN) with microglial activation in patients with primary and secondary tauopathies. *Mol Psychiatry*. 2023;28:4438-50. doi:10.1038/s41380-023-02188-8.
19. Pola I, Ashton NJ, Antonio De Bastiani M, Brum WS, Rahmouni N, Tan K, et al. Exploring inflammation-related protein expression and its relationship with TSPO PET in Alzheimer's disease. *Alzheimers Dement*. 2025;21:e70171. doi:10.1002/alz.70171.
20. Malpetti M, Swann P, Tsvetanov KA, Chouliaras L, Strauss A, Chikaura T, et al. Blood inflammation relates to neuroinflammation and survival in frontotemporal lobar degeneration. *Brain*. 2025;148:493-505. doi:10.1093/brain/awae269.
21. Best L, Ghadery C, Pavese N, Tai YF, Strafella AP. New and Old TSPO PET Radioligands for Imaging Brain Microglial Activation in Neurodegenerative Disease. *Curr Neurol Neurosci Rep*. 2019;19:24. doi:10.1007/s11910-019-0934-y.
22. Guo Q, Owen DR, Rabiner EA, Turkheimer FE, Gunn RN. Identifying improved TSPO PET imaging probes through biomathematics: the impact of multiple TSPO binding sites in vivo. *Neuroimage*. 2012;60:902-10. doi:10.1016/j.neuroimage.2011.12.078.
23. Kobayashi M, Jiang T, Telu S, Zoghbi SS, Gunn RN, Rabiner EA, et al. (11)C-DPA-713 has much greater specific binding to translocator protein 18 kDa (TSPO) in human brain than (11)C-(R)-PK11195. *J Cereb Blood Flow Metab*. 2018;38:393-403. doi:10.1177/0271678X17699223.
24. Owen DR, Yeo AJ, Gunn RN, Song K, Wadsworth G, Lewis A, et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. *J Cereb Blood Flow Metab*. 2012;32:1-5. doi:10.1038/jcbfm.2011.147.
25. Vettermann FJ, Harris S, Schmitt J, Unterrainer M, Lindner S, Rauchmann BS, et al. Impact of TSPO Receptor Polymorphism on [(18)F]GE-180 Binding in Healthy Brain and Pseudo-Reference Regions of Neurooncological and Neurodegenerative Disorders. *Life (Basel)*. 2021;11. doi:10.3390/life11060484.
26. Passamonti L, Rodriguez PV, Hong YT, Allinson KSJ, Bevan-Jones WR, Williamson D, et al. [(11)C]PK11195 binding in Alzheimer disease and progressive supranuclear palsy. *Neurology*. 2018;90:e1989-e96. doi:10.1212/WNL.0000000000005610.

27. Appleton J, Finn Q, Zanotti-Fregonara P, Yu M, Faridar A, Nakawah MO, et al. Brain inflammation co-localizes highly with tau in mild cognitive impairment due to early-onset Alzheimer's disease. *Brain*. 2025;148:119-32. doi:10.1093/brain/awae234.
28. Zhang M, Qian XH, Hu J, Zhang Y, Lin X, Hai W, et al. Integrating TSPO PET imaging and transcriptomics to unveil the role of neuroinflammation and amyloid-beta deposition in Alzheimer's disease. *Eur J Nucl Med Mol Imaging*. 2024;51:455-67. doi:10.1007/s00259-023-06446-3.
29. Palleis C, Sauerbeck J, Beyer L, Harris S, Schmitt J, Morenas-Rodriguez E, et al. In Vivo Assessment of Neuroinflammation in 4-Repeat Tauopathies. *Mov Disord*. 2021;36:883-94. doi:10.1002/mds.28395.
30. Zanotti-Fregonara P, Pascual B, Rizzo G, Yu M, Pal N, Beers D, et al. Head-to-Head Comparison of (11)C-PBR28 and (18)F-GE180 for Quantification of the Translocator Protein in the Human Brain. *J Nucl Med*. 2018;59:1260-6. doi:10.2967/jnumed.117.203109.
31. Zanotti-Fregonara P, Pascual B, Veronese M, Yu M, Beers D, Appel SH, et al. Head-to-head comparison of (11)C-PBR28 and (11)C-ER176 for quantification of the translocator protein in the human brain. *Eur J Nucl Med Mol Imaging*. 2019;46:1822-9. doi:10.1007/s00259-019-04349-w.
32. Hoglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. *Mov Disord*. 2017;32:853-64. doi:10.1002/mds.26987.
33. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*. 2011;7:270-9. doi:10.1016/j.jalz.2011.03.008.
34. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr., Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*. 2011;7:263-9. doi:10.1016/j.jalz.2011.03.005.
35. Golbe LI, Ohman-Strickland PA. A clinical rating scale for progressive supranuclear palsy. *Brain*. 2007;130:1552-65. doi:10.1093/brain/awm032.
36. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res*. 1975;12:189-98. doi:10.1016/0022-3956(75)90026-6.
37. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc*. 2005;53:695-9. doi:10.1111/j.1532-5415.2005.53221.x.
38. Hammers A, Allom R, Koeppe MJ, Free SL, Myers R, Lemieux L, et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. *Hum Brain Mapp*. 2003;19:224-47. doi:10.1002/hbm.10123.
39. Kovacs GG, Lukic MJ, Irwin DJ, Arzberger T, Respondek G, Lee EB, et al. Distribution patterns of tau pathology in progressive supranuclear palsy. *Acta Neuropathol*. 2020;140:99-119. doi:10.1007/s00401-020-02158-2.
40. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol*. 1991;82(4):239-59. doi: 10.1007/BF00308809.
41. Mattiace LA, Davies P, Yen SH, Dickson DW. Microglia in cerebellar plaques in Alzheimer's disease. *Acta Neuropathol*. 1990;80(5):493-8. doi: 10.1007/BF00294609.
42. Lyoo CH, Ikawa M, Liow JS, Zoghbi SS, Morse CL, Pike VW, et al. Cerebellum Can Serve As a Pseudo-Reference Region in Alzheimer Disease to Detect Neuroinflammation Measured with PET Radioligand Binding to Translocator Protein. *J Nucl Med*. 2015;56(5):701-6. doi: 10.2967/jnumed.114.146027.
43. Team RC. R: A Language and Environment for Statistical Computing. . R Foundation for Statistical Computing, Vienna, Austria. 2023.

44. van Steenoven I, Aarsland D, Hurtig H, Chen-Plotkin A, Duda JE, Rick J, et al. Conversion between mini-mental state examination, montreal cognitive assessment, and dementia rating scale-2 scores in Parkinson's disease. *Mov Disord*. 2014;29:1809-15. doi:10.1002/mds.26062.
45. Cummings JL. Maximizing the benefit and managing the risk of anti-amyloid monoclonal antibody therapy for Alzheimer's disease: Strategies and research directions. *Neurotherapeutics*. 2025:e00570. doi:10.1016/j.neurot.2025.e00570.
46. Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD, Sr., Jagust WJ, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. *Alzheimers Dement*. 2015;11:1-15 e1-4. doi:10.1016/j.jalz.2014.07.003.
47. Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. *JAMA*. 2023;330:512-27. doi:10.1001/jama.2023.13239.
48. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in Early Alzheimer's Disease. *N Engl J Med*. 2023;388:9-21. doi:10.1056/NEJMoa2212948.
49. Villemagne VL, Leuzy A, Bohorquez SS, Bullich S, Shimada H, Rowe CC, et al. CenTauR: Toward a universal scale and masks for standardizing tau imaging studies. *Alzheimers Dement (Amst)*. 2023;15:e12454. doi:10.1002/dad2.12454.
50. Lussier FZ, Povala G, Bauer-Negrini G, Amaral L, Cehula J, Fine DJ, et al. Longitudinal multicenter head-to-head harmonization of tau-PET tracers: an overview of the HEAD study cohort. *Alzheimer's & Dementia*. 2025;20. doi:10.1002/alz.094013.
51. Owen DR, Yeo AJ, Gunn RN, Song K, Wadsworth G, Lewis A, et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. *J Cereb Blood Flow Metab*. 2012;32(1):1-5. doi: 10.1038/jcbfm.2011.147.
52. Vettermann FJ, Harris S, Schmitt J, Unterrainer M, Lindner S, Rauchmann BS, et al. Impact of TSPO Receptor Polymorphism on [18F]GE-180 Binding in Healthy Brain and Pseudo-Reference Regions of Neurooncological and Neurodegenerative Disorders. *Life (Basel)*. 2021;11(6):484. doi: 10.3390/life11060484.
53. Heneka MT, van der Flier WM, Jessen F, Hoozemans J, Thal DR, Boche D, et al. Neuroinflammation in Alzheimer disease. *Nat Rev Immunol*. 2025;25:321-52. doi:10.1038/s41577-024-01104-7.
54. Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Alzheimer's disease drug development pipeline: 2024. *Alzheimers Dement (N Y)*. 2024;10:e12465. doi:10.1002/trc2.12465.
55. Dickson DW, Rademakers R, Hutton ML. Progressive supranuclear palsy: pathology and genetics. *Brain Pathol*. 2007;17:74-82. doi:10.1111/j.1750-3639.2007.00054.x.
56. Braak H, Alafuzoff I, Arzberger T, Kretschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. *Acta Neuropathol*. 2006;112:389-404. doi:10.1007/s00401-006-0127-z.
57. Biechele G, Rauchmann BS, Janowitz D, Buerger K, Franzmeier N, Weidinger E, et al. Associations between sex, body mass index and the individual microglial response in Alzheimer's disease. *J Neuroinflammation*. 2024;21:30. doi:10.1186/s12974-024-03020-y.
58. Biechele G, Franzmeier N, Blume T, Ewers M, Luque JM, Eckenweber F, et al. Glial activation is moderated by sex in response to amyloidosis but not to tau pathology in mouse models of neurodegenerative diseases. *J Neuroinflammation*. 2020;17:374. doi:10.1186/s12974-020-02046-2.
59. Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. *Nat Rev Cardiol*. 2018;15:505-22. doi:10.1038/s41569-018-0064-2.
60. Tuisku J, Plaven-Sigray P, Gaiser EC, Airas L, Al-Abdulrasul H, Bruck A, et al. Effects of age, BMI and sex on the glial cell marker TSPO - a multicentre [(11)C]PBR28 HRRT PET study. *Eur J Nucl Med Mol Imaging*. 2019;46:2329-38. doi:10.1007/s00259-019-04403-7.
61. Knyzeliene A, Wimberley C, MacAskill MG, Alcaide-Corral CJ, Morgan TEF, Henry MC, et al. Sexually dimorphic murine brain uptake of the 18 kDa translocator protein PET radiotracer [(18)F]LW223. *Brain Commun*. 2024;6:fcae008. doi:10.1093/braincomms/fcae008.

62. Maccioni L, Brusaferrri L, Barzon L, Schubert JJ, Nettis MA, Cousins O, et al. A novel blood-free analytical framework for the quantification of neuroinflammatory load from TSPO PET Imaging. *Res Sq*. 2025. doi:10.21203/rs.3.rs-5924801/v1.
63. Muller L, Di Benedetto S, Muller V. From Homeostasis to Neuroinflammation: Insights into Cellular and Molecular Interactions and Network Dynamics. *Cells*. 2025;14. doi:10.3390/cells14010054.
64. Fan Z, Brooks DJ, Okello A, Edison P. An early and late peak in microglial activation in Alzheimer's disease trajectory. *Brain*. 2017;140:792-803. doi:10.1093/brain/aww349.

Declarations

Acknowledgments

We thank our participant volunteers for their participation in this study, the clinical staff and the research nurses for their contribution, and the East Anglia Dementias and Neurodegenerative Diseases Research Network (DeNDRoN) for help with subject recruitment. We thank the UK Dementia Research Institute (UKDRI) at Cambridge. We thank all our patients, their caregivers, cyclotron, radiochemistry, and the positron emission tomography imaging staff at LMU Munich. GE Healthcare made GE-180 cassettes available through an early access model. We thank all of our participants and their care partners who contributed to this work at the Montreal Neurological Institute, McGill University.

For the purpose of open access, the authors have applied a Creative Commons Attribution (CC BY) license to any Author Accepted Manuscript version arising from this submission.

Funding

Cambridge University: This study was co-funded by the Dementias Platform UK and Medical Research Council (MC_UU_00030/14; MR/T033371/1); Race Against Dementia Alzheimer's Research UK (ARUK-RADF2021A-010); Alzheimer's Research UK PhD Scholarship (ARUK-PhD2023-018); the Wellcome trust (220258); the Cambridge University Centre for Parkinson-Plus (RG95450); the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre (NIHR203312). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. This work is also supported by the UK Dementia Research Institute through UK DRI ltd, principally funded by the Medical Research Council.

LMU Munich: This study was supported by the German Center for Neurodegenerative Disorders (Deutsches Zentrum für Neurodegenerative Erkrankungen), Hirnliga (Manfred-Strohscheer Stiftung), and the German Research Foundation (Deutsche Forschungsgemeinschaft) under Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy, ID 390857198).

McGill University: The TRIAD cohort study data is supported by the Weston Brain Institute, Canadian Institutes of Health Research (CIHR) [MOP-11-51-31; RFN 152985, 159815, 162303], Canadian Consortium of Neurodegeneration and Aging (CCNA; MOP-11-51-31-team 1), Brain Canada Foundation (CFI Project 34874; 33397), the Fonds de Recherche du Québec – Santé (FRQS; 2020-VICO-279314; 2024 VICO-356138; <https://doi.org/10.69777/324345>;

<https://doi.org/10.69777/356138> and <https://doi.org/10.69777/312994>), and the Colin J Adair Charitable Foundation.

Competing Interests

The authors have no conflicts of interest to report related to this work. Unrelated to this work, JTO has received honoraria unrelated to this work as DSMB chair or member for TauRx, Axon, Eisai and Novo Nordisk, and has acted as a consultant for Biogen and Roche, and has received research support from Alliance Medical and Merck. JBR is a non-remunerated trustee of the Guarantors of Brain, Darwin College and the PSP Association (UK). He provides consultancy unrelated to the current work to Asceneuron, Astronautx, Astex, Alector, Booster Therapeutics, Curasen, CumulusNeuro, ClinicalInk, Draig Therapeutics, Eisai, Ferrer, Wave, SVHealth, and has research grants from AZ-Medimmune, Janssen, and Lilly as industry partners in the Dementias Platform UK. MM has acted as a consultant for Astex Pharmaceuticals. RP has received honoraria for advisory boards and speaker engagements from Roche, Eisai, Eli Lilly, Biogen, Janssen-Cilag, AstraZeneca, Schwabe, Grifols, Novo Nordisk, and Tabuk, and is a shareholder of Medotrax GmbH and Vistim Ltd. MB received speaker honoraria from GE healthcare, Roche, Iba, and Life Molecular Imaging and is an advisor of GE healthcare, MIAC, and Life Molecular Imaging. NF received speaker or consulting honoraria from GE healthcare, Eisai, Life molecular imaging and MSD.

Authors Contributions

MM, MB, and PRN were responsible for study conception and design. Patient recruitment, material preparation, and data collection were performed by NF, NR, JSG, AS, SNRC, CP, PSJ, TF, YH, FIA, RH, BSR, GM, JL, GH, JBR, RP, and JTO. Data analyses were performed by HC, NF, NR, JSG, TF, and YH. The first draft of the manuscript was written by HC and all authors commented on the previous versions of the manuscript. All authors read and approved the final manuscript.

Data Availability

Anonymized processed data can be shared upon request to the corresponding or senior authors. Raw data may also be requested but are likely to be subject to a data transfer agreement with restrictions required to comply with participant consent and data protection regulations.

Consent to participate

Participants with mental capacity gave their written informed consent to take part in the study. For those who lacked capacity, their participation followed the consultee process in accordance with the law.

Consent to publish

By providing written informed consent to take part in the study, participants consented to anonymised results being published.